One example is Amatuximab, a chimeric high-affinity monoclonal IgG1/k antibody targeting MSLN, which elicits cellular toxicity against MSLN-expressing tumour cells, and reduces invasive capacity and tumour sphere formation216. The gene discussed is MSLN; the disease is neoplasm.